title: [Medications in pregnancy].
abstract: Exaggerated caution or even deferment in the treatment of chronically ill mothers-to-be, for example, in the case of epilepsy, hypertension or bronchial asthma, may result in a dramatic worsening of the underlying disease and thus may threaten the further development of the fetus. On the other hand, an inadequate knowledge of the true risks of pharmacological treatment already applied in the early stages of pregnancy, leads to numerous abortions that are inappropriately indicated. As a basic rule, when planning pharmacological treatment in a pregnant woman, well tried and tested substances should be given preference over new drugs. If a pregnant woman has been exposed to an insufficiently tested substance as a result of ignorance of her pregnancy, recognized centers with appropriate data banks (www.reprotox.de) should be consulted.
authors.affiliation: Institut für Reproduktionstoxikologie KH St. Elisabeth (Akademisches Lehrkrankenhaus der Universität Ulm) Elisabethenstrage 17, D-88212 Ravensburg. paulus@reprotox.de
authors.forename: W
authors.initials: W
authors.lastname: Paulus
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology* / Q000517:prevention & control; D000025:Abortion, Eugenic; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D012307:Risk Factors